An engineered T-cell engager with selectivity for high mesothelin-expressing cells and activity in the presence of soluble mesothelin

References

• Perez P, Hoffman RW, Shaw S, Bluestone JA, Segal DM. Specific targeting of cytotoxic T cells by anti-T3 linked to anti-target cell antibody. Nature. 1985;316(6026):354–11. doi:10.1038/316354a0.
   PubMed Web of Science ®Google Scholar
• Staerz UD, Kanagawa O, Bevan MJ. Hybrid antibodies can target sites for attack by T cells. Nature. 1985;314(6012):628–631. doi:10.1038/314628a0.
   PubMed Web of Science ®Google Scholar
• Middelburg J, Kemper K, Engelberts P, Labrijn AF, Schuurman J, van Hall T. Overcoming challenges for CD3-Bispecific antibody therapy in solid tumors. Cancers Basel. 2021;13(2):287. doi:10.3390/cancers13020287.
   PubMed Web of Science ®Google Scholar
• Singh A, Dees S, Grewal IS. Overcoming the challenges associated with CD3+ T-cell redirection in cancer. Br J Cancer. 2021;124(6):1037–1048. doi:10.1038/s41416-020-01225-5.
   PubMed Web of Science ®Google Scholar
• Slaga D, Ellerman D, Lombana TN, Vij R, Li J, Hristopoulos M, Clark R, Johnston J, Shelton A, Mai E, et al. Avidity-based binding to HER2 results in selective killing of HER2-overexpressing cells by anti-HER2/CD3. Sci Transl Med. 2018;10(463). doi:10.1126/scitranslmed.aat5775.
   PubMed Web of Science ®Google Scholar
• Wang S, Chen K, Lei Q, Ma P, Yuan AQ, Zhao Y, Jiang Y, Fang H, Xing S, Fang Y, et al. The state of the art of bispecific antibodies for treating human malignancies. EMBO Mol Med. 2021;13(9):e14291. doi:10.15252/emmm.202114291.
   PubMed Web of Science ®Google Scholar
• Weidemann S, Gagelmann P, Gorbokon N, Lennartz M, Menz A, Luebke AM, Kluth M, Hube-Magg C, Blessin NC, Fraune C, et al. Mesothelin expression in human tumors: A tissue microarray study on 12,679 tumors. Biomedicines. 2021;9(4):397. doi:10.3390/biomedicines9040397.
   PubMed Web of Science ®Google Scholar
• Hassan R, Thomas A, Alewine C, Le DT, Jaffee EM, Pastan I. Mesothelin immunotherapy for cancer: Ready for prime time? J Clin Oncol. 2016;34(34):4171–4179. doi:10.1200/JCO.2016.68.3672.
   PubMed Web of Science ®Google Scholar
• Kachala SS, Bograd AJ, Villena-Vargas J, Suzuki K, Servais EL, Kadota K, Chou J, Sima CS, Vertes E, Rusch VW, et al. Mesothelin overexpression is a marker of tumor aggressiveness and is associated with reduced recurrence-free and overall survival in early-stage lung adenocarcinoma. Clin Cancer Res. 2014;20(4):1020–1028. doi:10.1158/1078-0432.CCR-13-1862.
   PubMed Web of Science ®Google Scholar
• Thomas A, Chen Y, Steinberg SM, Luo J, Pack S, Raffeld M, Abdullaev Z, Alewine C, Rajan A, Giaccone G, et al. High mesothelin expression in advanced lung adenocarcinoma is associated with KRAS mutations and a poor prognosis. Oncotarget. 2015;6(13):11694–11703. doi:10.18632/oncotarget.3429.
   PubMed Web of Science ®Google Scholar
• Tozbikian G, Brogi E, Kadota K, Catalano J, Akram M, Patil S, Ho AY, Reis-Filho JS, Weigelt B, Norton L, et al. Mesothelin expression in triple negative breast carcinomas correlates significantly with basal-like phenotype, distant metastases and decreased survival. PLoS One. 2014;9(12):e114900. doi:10.1371/journal.pone.0114900.
   PubMed Web of Science ®Google Scholar
• Winter JM, Tang LH, Klimstra DS, Brennan MF, Brody JR, Rocha FG, Jia X, Qin L-X, D’Angelica MI, DeMatteo RP, et al. A novel survival-based tissue microarray of pancreatic cancer validates MUC1 and mesothelin as biomarkers. PLoS One. 2012;7(7):e40157. doi:10.1371/journal.pone.0040157.
   PubMed Web of Science ®Google Scholar
• Chang K, Pastan I, Willingham MC. Isolation and characterization of a monoclonal antibody, K1, reactive with ovarian cancers and normal mesothelium. Int J Cancer. 1992;50(3):373–381. doi:10.1002/ijc.2910500308.
   PubMed Web of Science ®Google Scholar
• Pastan I, Hassan R. Discovery of mesothelin and exploiting it as a target for immunotherapy. Cancer Res. 2014;74(11):2907–2912. doi:10.1158/0008-5472.CAN-14-0337.
   PubMed Web of Science ®Google Scholar
• Faust JR, Hamill D, Kolb EA, Gopalakrishnapillai A, Barwe SP. Mesothelin: An immunotherapeutic target beyond solid tumors. Cancers Basel. 2022;14(6):1550. doi:10.3390/cancers14061550.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Chertov O, Zhang J, Hassan R, Pastan I. Cytotoxic activity of immunotoxin SS1P is modulated by TACE-dependent mesothelin shedding. Cancer Res. 2011;71(17):5915–5922. doi:10.1158/0008-5472.CAN-11-0466.
   PubMed Web of Science ®Google Scholar
• Yoon A, Lee S, Lee S, Lim S, Park Y-Y, Song E, Kim D-S, Kim K, Lim Y. A novel T cell-engaging bispecific antibody for treating mesothelin-positive solid tumors. Biomolecules. 2020;10(3):399. doi:10.3390/biom10030399.
   PubMed Web of Science ®Google Scholar
• Egan TJ, Diem D, Weldon R, Neumann T, Meyer S, Urech DM. Novel multispecific heterodimeric antibody format allowing modular assembly of variable domain fragments. MAbs. 2017;9(1):68–84. doi:10.1080/19420862.2016.1248012.
   PubMed Web of Science ®Google Scholar
• Warmuth S, Gunde T, Snell D, Brock M, Weinert C, Simonin A, Hess C, Tietz J, Johansson M, Spiga FM, et al. Engineering of a trispecific tumor-targeted immunotherapy incorporating 4-1BB co-stimulation and PD-L1 blockade. Oncoimmunology. 2021;10(1):2004661. doi:10.1080/2162402X.2021.2004661.
   PubMed Web of Science ®Google Scholar
• Douvdevani A, Rapoport J, Konforty A, Argov S, Ovnat A, Chaimovitz C. Human peritoneal mesothelial cells synthesize IL-1α and β. Kidney Int. 1994;46(4):993–1001. doi:10.1038/ki.1994.359.
   PubMed Web of Science ®Google Scholar
• Liu X, Onda M, Watson N, Hassan R, Ho M, Bera TK, Wei J, Chakraborty A, Beers R, Zhou Q, et al. Highly active CAR T cells that bind to a juxtamembrane region of mesothelin and are not blocked by shed mesothelin. Proc Natl Acad Sci USA. 2022;119(19):e2202439119. doi:10.1073/pnas.2202439119.
   PubMed Web of Science ®Google Scholar
• Chong EA, Melenhorst JJ, Lacey SF, Ambrose DE, Gonzalez V, Levine BL, June CH, Schuster SJ. PD-1 blockade modulates chimeric antigen receptor (CAR)–modified T cells: refueling the CAR. Blood. 2017;129(8):1039–1041. doi:10.1182/blood-2016-09-738245.
   PubMed Web of Science ®Google Scholar
• Sam J, Colombetti S, Fauti T, Roller A, Biehl M, Fahrni L, Nicolini V, Perro M, Nayak T, Bommer E, et al. Combination of T-Cell bispecific antibodies with PD-L1 checkpoint inhibition elicits superior anti-tumor activity. Front Oncol. 2020;10:575737. doi:10.3389/fonc.2020.575737.
   PubMed Web of Science ®Google Scholar
• Adusumilli PS, Zauderer MG, Rivière I, Solomon SB, Rusch VW, O’Cearbhaill RE, Zhu A, Cheema W, Chintala NK, Halton E, et al. A Phase I trial of regional mesothelin-targeted CAR T-cell therapy in patients with malignant pleural disease, in combination with the Anti–PD-1 agent pembrolizumab. Cancer Discov. 2021;11(11):2748–2763. doi:10.1158/2159-8290.CD-21-0407.
   PubMed Web of Science ®Google Scholar
• Liu G, Zhang Q, Li D, Zhang L, Gu Z, Liu J, Liu G, Yang M, Gu J, Cui X, et al. PD-1 silencing improves anti-tumor activities of human mesothelin-targeted CAR T cells. Hum Immunol. 2021;82(2):130–138. doi:10.1016/j.humimm.2020.12.002.
   PubMed Web of Science ®Google Scholar
• Wang Z, Li N, Feng K, Chen M, Zhang Y, Liu Y, Yang Q, Nie J, Tang N, Zhang X, et al. Phase I study of CAR-T cells with PD-1 and TCR disruption in mesothelin-positive solid tumors. Cell Mol Immunol. 2021;18(9):2188–2198. doi:10.1038/s41423-021-00749-x.
   PubMed Web of Science ®Google Scholar
• Schreiner J, Thommen DS, Herzig P, Bacac M, Klein C, Roller A, Belousov A, Levitsky V, Savic S, Moersig W, et al. Expression of inhibitory receptors on intratumoral T cells modulates the activity of a T cell-bispecific antibody targeting folate receptor. Oncoimmunology. 2016;5(2):e1062969. doi:10.1080/2162402X.2015.1062969.
   PubMed Web of Science ®Google Scholar
• Hagerty BL, Pegna GJ, Xu J, Tai C-H, Alewine C. Mesothelin-Targeted recombinant immunotoxins for solid tumors. Biomolecules. 2020;10(7):973. doi:10.3390/biom10070973.
   PubMed Web of Science ®Google Scholar
• Molloy ME, Austin RJ, Lemon BD, Aaron WH, Ganti V, Jones A, Jones SD, Strobel KL, Patnaik P, Sexton K, et al. Preclinical characterization of HPN536, a trispecific, T-Cell–Activating protein construct for the treatment of mesothelin-expressing solid tumors. Clin Cancer Res. 2021;27(5):1452–1462. doi:10.1158/1078-0432.CCR-20-3392.
   PubMed Web of Science ®Google Scholar
• Zhang J, Qiu S, Zhang Y, Merino M, Fetsch P, Avital I, Filie A, Pastan I, Hassan R. Loss of mesothelin expression by mesothelioma cells grown in vitro determines sensitivity to anti-mesothelin immunotoxin SS1P. Anticancer Res. 2012;32:5151–5158.
   PubMed Web of Science ®Google Scholar
• Awuah P, Bera TK, Folivi M, Chertov O, Pastan I. Reduced shedding of surface mesothelin improves efficacy of mesothelin-targeting recombinant immunotoxins. Mol Cancer Ther. 2016;15(7):1648–1655. doi:10.1158/1535-7163.MCT-15-0863.
   PubMed Web of Science ®Google Scholar
• Zhou S, Liu M, Ren F, Meng X, Yu J. The landscape of bispecific T cell engager in cancer treatment. Biomark Res. 2021;9(1):38. doi:10.1186/s40364-021-00294-9.
   PubMed Web of Science ®Google Scholar
• Köhnke T, Krupka C, Tischer J, Knösel T, Subklewe M. Increase of PD-L1 expressing B-precursor ALL cells in a patient resistant to the CD19/CD3-bispecific T cell engager antibody blinatumomab. J Hematol Oncol. 2015;8(1):111. doi:10.1186/s13045-015-0213-6.
   PubMed Web of Science ®Google Scholar
• Krupka C, Kufer P, Kischel R, Zugmaier G, Lichtenegger FS, Köhnke T, Vick B, Jeremias I, Metzeler KH, Altmann T, et al. Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism. Leukemia. 2016;30(2):484–491. doi:10.1038/leu.2015.214.
   PubMed Web of Science ®Google Scholar
• Laszlo GS, Gudgeon CJ, Harrington KH, Walter RB. T-cell ligands modulate the cytolytic activity of the CD33/CD3 BiTE antibody construct, AMG 330. Blood Cancer J. 2015;5(8):e340. doi:10.1038/bcj.2015.68.
   PubMed Web of Science ®Google Scholar
• Osada T, Patel SP, Hammond SA, Osada K, Morse MA, Lyerly HK. CEA/CD3-bispecific T cell-engaging (BiTE) antibody-mediated T lymphocyte cytotoxicity maximized by inhibition of both PD1 and PD-L1. Cancer Immunol Immunother. 2015;64(6):677–688. doi:10.1007/s00262-015-1671-y.
   PubMed Web of Science ®Google Scholar
• Herrmann M, Krupka C, Deiser K, Brauchle B, Marcinek A, Ogrinc Wagner A, Rataj F, Mocikat R, Metzeler KH, Spiekermann K, et al. Bifunctional PD-1 × αCD3 × αCD33 fusion protein reverses adaptive immune escape in acute myeloid leukemia. Blood. 2018;132(23):2484–2494. doi:10.1182/blood-2018-05-849802.
   PubMed Web of Science ®Google Scholar
• Kobold S, Pantelyushin S, Rataj F, Vom Berg J. Rationale for combining bispecific T cell activating antibodies with checkpoint blockade for cancer therapy. Front Oncol. 2018;8:285. doi:10.3389/fonc.2018.00285.
   PubMed Web of Science ®Google Scholar
• Chen N, Morello A, Tano Z, Adusumilli PS. CAR T-cell intrinsic PD-1 checkpoint blockade: A two-in-one approach for solid tumor immunotherapy. Oncoimmunology. 2017;6(2):e1273302. doi:10.1080/2162402X.2016.1273302.
   PubMed Web of Science ®Google Scholar
• Cherkassky L, Morello A, Villena-Vargas J, Feng Y, Dimitrov DS, Jones DR, Sadelain M, Adusumilli PS. Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition. J Clin Invest. 2016;126(8):3130–3144. doi:10.1172/JCI83092.
   PubMed Web of Science ®Google Scholar
• Crawford A, Haber L, Kelly MP, Vazzana K, Canova L, Ram P, Pawashe A, Finney J, Jalal S, Chiu D, et al. A mucin 16 bispecific T cell–engaging antibody for the treatment of ovarian cancer. Sci Transl Med. 2019;11(497). doi:10.1126/scitranslmed.aau7534.
   Web of Science ®Google Scholar
• Tian Z, Liu M, Zhang Y, Wang X. Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies. J Hematol Oncol. 2021;14(1):75. doi:10.1186/s13045-021-01084-4.
   PubMed Web of Science ®Google Scholar
• Haber L, Olson K, Kelly MP, Crawford A, DiLillo DJ, Tavaré R, Ullman E, Mao S, Canova L, Sineshchekova O, et al. Generation of T-cell-redirecting bispecific antibodies with differentiated profiles of cytokine release and biodistribution by CD3 affinity tuning. Sci Rep. 2021;11(1):14397. doi:10.1038/s41598-021-93842-0.
   PubMed Web of Science ®Google Scholar